BioSpace News Archive

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced that the Company has joined the Russell Microcap® Index.

Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, announced an award of a $3 million grant from the National Institute of Aging at National Institutes of Health.

Galera Therapeutics, Inc. announced completion of enrollment in its pivotal Phase 3 ROMAN trial of avasopasem manganese for the treatment of severe oral mucositis in patients with locally advanced head and neck cancer undergoing standard-of-care radiotherapy.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index, effective after the U.S. market opens, June 28, 2021, as part of the annual reconstitution of the Russell stock indexes.

Inspection machines are combination or sequence of machines that are used to inspect the quality of the product in terms of packaging, packaging component, weight, leakage, and dimension so as to maintain consistency throughout the production line.

Fact.MR, Dubai: The global nizatidine market is expected to record a steady growth due to the rising prevalence of gastrointestinal diseases such as celiac diseases, indigestion, and acid reflux.

Phico Therapeutics Ltd, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, announced the appointment of Richard Nagle as Chair of its Board of Directors.

Partner Therapeutics, Inc. announced top-line results of the U.S.-based iLeukPulm clinical trial of inhaled Leukine ) in hospitalized COVID-19 patients.1 This prospective, randomized, controlled, open-label study was conducted at 11 U.S. hospitals.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced positive interim results from the Single Ascending Dose portion of the Phase 1 clinical trial of KT-474, demonstrating the first degrader proof-of-mechanism in targeted protein degradation in a randomized, placebo-controlled healthy volunteer study.

MaaT Pharma, a clinical-stage biotechnology company focused on developing Microbiome Ecosystem Therapies in oncology, announced that the Data Safety and Monitoring Board recommended to proceed to the fourth cohort of the dose-finding Phase 1b CIMON clinical trial, without modifications.